Samsara BioCapital's book
38 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Parabilis Medicines | Drug Discovery | $920.0M | — | — | |
| Delfi Diagnostics | — | $725.0M | — | — | |
| Abcuro | Drug Discovery | $700.0M | — | — | |
| Candid Therapeutics | Drug Discovery | $657.0M | — | — | |
| SpyGlass Pharma (NAS: SGP) | Surgical Devices | $510.6M | — | — | |
| Synthekine | — | $500.0M | — | — | |
| Dewpoint Therapeutics | — | $500.0M | — | — | |
| Egenesis | — | $330.0M | — | — | |
| OrsoBio | — | $310.0M | — | — | |
| Pathalys Pharma | — | $295.0M | — | — | |
| + 28 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 38 recorded positions
- ·Watchlist + alerts for Samsara BioCapital's activity
Create free account
No card required